Purine nucleoside phosphorylases as targets for transition-state analog design

doi:10.1017/CBO9780511730412.017

15 - Purine nucleoside phosphorylases as targets for transition-state analog design

from PART III - APPLICATIONS TO DRUG DISCOVERY

Published online by Cambridge University Press: 06 July 2010

Andrew S. Murkin and

Vern L. Schramm

Edited by

Kenneth M. Merz, Jr ,

Dagmar Ringe and

Charles H. Reynolds

Show author details

Kenneth M. Merz, Jr: Affiliation:
University of Florida
Dagmar Ringe: Affiliation:
Brandeis University, Massachusetts
Charles H. Reynolds: Affiliation:
Johnson & Johnson Pharmaceutical Research & Development

Book contents

Get access

Summary

INTRODUCTION

Among the most powerful enzyme-targeted drugs are those that bear a strong resemblance to the transition state of the chemical reaction undergoing catalysis. This chapter illustrates that experimental determination of enzymatic transition-state structure permits chemically stable analogs to be designed. Mimics of these transition states exhibit binding affinities exceeding those of the substrates by factors of greater than 106. To appreciate this approach to drug design, it is necessary to understand the nature of transition-state formation and how it relates to the strong binding interactions between enzymes and transition-state analogs.

Enzymatic transition-state formation

All chemical reactions proceed through at least one transition state, an unstable structure of maximal energy along the reaction coordinate. Having a lifetime of under 100 fs (10-13 s), the time required for a single bond vibration, the transition state is the most unstable species along a chemical reaction coordinate. In the absence of a catalyst, the probability of transition-state formation is extremely low. Enzymes achieve great catalytic reaction rates by providing appropriately positioned functional groups within the active site, which interact with and distort the substrate toward the transition state by dynamic motions of the complex.

Although the physical means of enzymatic transition-state formation remain the subject of scientific debate, several theories have been proffered. In the early 1940s, Linus Pauling postulated that enzymes bind most optimally not to the normal substrate molecule but rather to the substrate molecule in a strained configuration corresponding to the “activated complex.” He suggested that various attractive forces with the enzyme cause the substrate to adopt the strained configuration, thereby favoring the chemical reaction and accounting for the lowered activation energy of the catalyzed reaction.

Information

Type: Chapter
Information: Drug Design
Structure- and Ligand-Based Approaches
, pp. 215 - 247

DOI: https://doi.org/10.1017/CBO9780511730412.017 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Pauling, L.Molecular architecture and biological reactions. Chem. Eng. News 1946, 24, 1375–1377.Google Scholar

Wolfenden, R.Transition state analogues for enzyme catalysis. Nature 1969, 223, 704–705.Google Scholar

Wolfenden, R.Analog approaches to the structure of the transition state in enzyme reactions. Acc. Chem. Res. 1972, 5, 10–18.Google Scholar

Jencks, W.Binding energy, specificity, and enzymic catalysis: the Circe effect. Adv. Enzymol. Relat. Areas Mol. Biol. 1975, 43, 219–410.Google Scholar

Anderson, V.Ground state destabilization. In: Encyclopedia of Life Sciences. Chichester: John Wiley & Sons, Ltd.; 2001, 1–5.

Shih, I.; Been, M.Catalytic strategies of the hepatitis delta virus ribozymes. Annu. Rev. Biochem. 2002, 71, 887–917.Google Scholar

Wu, N.; Mo, Y.; Gao, J.; Pai, E.Electrostatic stress in catalysis: structure and mechanism of the enzyme orotidine monophosphate decarboxylase. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2017–2022.Google Scholar

Amyes, T. L.; Wood, B. M.; Chan, K.; Gerlt, J. A.; Richard, J. P.Formation and stability of a vinyl carbanion at the active site of orotidine 5′-monophosphate decarboxylase: pKa of the C-6 proton of enzyme-bound UMP. J. Am. Chem. Soc. 2008, 130, 1574–1575.Google Scholar

Bruice, T. C.; Lightstone, F. C.Ground state and transition state contributions to the rates of intramolecular and enzymatic reactions. Acc. Chem. Res. 1999, 32, 127–136.Google Scholar

Lightstone, F. C.; Bruice, T. C.Ground state conformations and entropic and enthalpic factors in the efficiency of intramolecular and enzymatic reactions. 1. Cyclic anhydride formation by substituted glutarates, succinate, and 3,6-endoxo-Δ4-tetrahydrophthalate monophenyl esters. J. Am. Chem. Soc. 1996, 118, 2595–2605.Google Scholar

Antoniou, D.; Basner, J.; Núñez, S.; Schwartz, S.Computational and theoretical methods to explore the relation between enzyme dynamics and catalysis. Chem. Rev. 2006, 106, 3170–3187.Google Scholar

Kohen, A.; Cannio, R.; Bartolucci, S.; Klinman, J.Enzyme dynamics and hydrogen tunnelling in a thermophilic alcohol dehydrogenase. Nature 1999, 399, 496–499.Google Scholar

Agarwal, P.; Billeter, S.; Rajagopalan, P.; Benkovic, S.; Hammes-Schiffer, S.Network of coupled promoting motions in enzyme catalysis. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 2794–2799.Google Scholar

Wong, K.; Selzer, T.; Benkovic, S.; Hammes-Schiffer, S.Impact of distal mutations on the network of coupled motions correlated to hydride transfer in dihydrofolate reductase. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 6807–6812.Google Scholar

Nunez, S.; Antoniou, D.; Schramm, V. L.; Schwartz, S. D.Promoting vibrations in human purine nucleoside phosphorylase: a molecular dynamics and hybrid quantum mechanical/molecular mechanical study. J. Am. Chem. Soc. 2004, 126, 15720–15729.Google Scholar

Saen-Oon, S.; Ghanem, M.; Schramm, V.; Schwartz, S.Remote mutations and active site dynamics correlate with catalytic properties of purine nucleoside phosphorylase. Biophys. J. 2008, 94(10), 4078–4088.Google Scholar

Lienhard, G.Enzymatic catalysis and transition-state theory. Science 1973, 180, 149–154.Google Scholar

Wolfenden, R.; Kati, W. M.Testing the limits of protein-ligand binding discrimination with transition-state analogue inhibitors. Acc. Chem. Res. 1991, 24, 209–215.Google Scholar

Wolfenden, R.Conformational aspects of inhibitor design: enzyme-substrate interactions in the transition state. Bioorg. Med. Chem. 1999, 7, 647–652.Google Scholar

Schramm, V.Enzymatic transition state theory and transition state analogue design. J. Biol. Chem. 2007, 282, 28297–28300.Google Scholar

Schramm, V.Enzymatic transition states and transition state analog design. Annu. Rev. Biochem. 1998, 67, 693–720.Google Scholar

Hammond, G. S.A correlation of reaction rates. J. Am. Chem. Soc. 1955, 77, 334–338.Google Scholar

Jencks, W. In: Catalysis in Chemistry and Enzymology. Dover: New York, 1987, 170–182.

Schramm, V.Enzymatic transition states: thermodynamics, dynamics and analogue design. Arch. Biochem. Biophys. 2005, 433, 13–26.Google Scholar

Cleland, W.Isotope Effects: Determination of enzyme transition state structure. Methods Enzymol. 1995, 249, 341–373.Google Scholar

Parkin, D. W. In: Enzyme Mechanism from Isotope Effects, Cook, P. F.; Ed. Boca Raton: CRC Press; 1991, 269–290.

Rodgers, J.; Femec, D. A.; Schowen, R. L.Isotopic mapping of transition-state structural features associated with enzymic catalysis of methyl transfer. J. Am. Chem. Soc. 1982, 104, 3263–3268.Google Scholar

Sunhel, J.; Schowen, R. In: Enzyme Mechanism from Isotope Effects, Cook, P. F.; Ed. Boca Raton: CRC Press; 1991, 3–36.

Huskey, W. In: Enzyme Mechanism from Isotope Effects, Cook, P. F.; Ed. Boca Raton: CRC Press; 1991, 37–72.

Berti, P. J.; Tanaka, K. S. E. Transition state analysis using multiple kinetic isotope effects: mechanisms of enzymatic and non-enzymatic glycoside hydrolysis and transfer. Adv. Phys. Org. Chem. 2002, 37, 239–314.Google Scholar

Rose, I.The isotope trapping method: desorption rates of productive e.s complexes. Methods Enzymol. 1980, 64, 47–59.Google Scholar

Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Rega, N.; Salvador, P.; Dannenberg, J. J.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Baboul, A. G.; Stefanov, B. B.; G. Liu, A. L.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Andres, J. L.; Gonzalez, C.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A.; Revision A.11.2 ed.; Gaussian, Inc.: Pittsburgh, PA, 2001.

Saunders, M.; Laidig, K. E.; Wolfsberg, M.Theoretical calculation of equilibrium isotope effects using ab initio force constants: application to NMR isotope perturbation studies. J. Am. Chem. Soc. 1989, 111, 8989–8994.Google Scholar

Anisimov, V.; Paneth, P.ISOEFF98: a program for studies of isotope effects using hessian modifications. J. Math. Chem. 1999, 26, 75–86.Google Scholar

Melander, L.; Saunders, W. H.Reaction Rates of Isotopic Molecules. New York, NY: Wiley & Sons; 1980.

Bigeleisen, J.The relative reaction velocities of isotopic molecules. J. Chem. Phys. 1949, 17, 675–678.Google Scholar

Bigeleisen, J.; Wolsberg, M.Theoretical and experimental aspects of isotope effects in chemical kinetics. Adv. Chem. Phys. 1958, 1, 15–76.Google Scholar

Streitwieser, A.; Jagow, R. H.; Fahey, R. C.; Suzuki, S.Kinetic isotope effects in the acetolyses of deuterated cyclopentyl tosylates. J. Am. Chem. Soc. 1958, 80, 2326–2332.Google Scholar

Northrop, D.The expression of isotope effects on enzyme-catalyzed reactions. Annu. Rev. Biochem. 1981, 50, 103–131.Google Scholar

Birck, M.; Schramm, V.Binding causes the remote [5′-3H]thymidine kinetic isotope effect in human thymidine phosphorylase. J. Am. Chem. Soc. 2004, 126, 6882–6883.Google Scholar

Murkin, A. S.; Birck, M. R.; Rinaldo-Matthis, A.; Shi, W. X.; Taylor, E. A.; Almo, S. C.; Schramm, V. L.Neighboring group participation in the transition state of human purine nucleoside phosphorylase. Biochemistry 2007, 46, 5038–5049.Google Scholar

Ruszczycky, M.; Anderson, V.Interpretation of V/K isotope effects for enzymatic reactions exhibiting multiple isotopically sensitive steps. J. Theor. Biol. 2006, 243, 328–342.Google Scholar

Giblett, E. R.; Ammann, A. J.; Wara, D. W.; Sandman, R.; Diamond, L. K.Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1975, 1, 1010–1013.Google Scholar

Markert, M.; Finkel, B.; McLaughlin, T.; Watson, T.; Collard, H.; McMahon, C.; Andrews, L.; Barrett, M.; Ward, F.Mutations in purine nucleoside phosphorylase deficiency. Hum. Mutat. 1997, 9, 118–121.Google Scholar

Markert, M.Purine nucleoside phosphorylase deficiency. Immunodef. Rev. 1991, 3, 45–81.Google Scholar

Oliver, F.; Collins, M.; López-Rivas, A.dNTP pools imbalance as a signal to initiate apoptosis. Experientia 1996, 52, 995–1000.Google Scholar

Zoltewicz, J.; Clark, D.; Sharpless, T.; Grahe, G.Kinetics and mechanism of the acid-catalyzed hydrolysis of some purine nucleosides. J. Am. Chem. Soc. 1970, 92, 1741–1749.Google Scholar

McCann, J.; Berti, P.Transition state analysis of acid-catalyzed dAMP hydrolysis. J. Am. Chem. Soc. 2007, 129, 7055–7064.Google Scholar

Krenitsky, T.Purine nucleoside phosphorylase: kinetics, mechanism, and specificity. Mol. Pharmacol. 1967, 3, 526–536.Google Scholar

Kim, B.; Cha, S.; Parks, R. J.Purine nucleoside phosphorylase from human erythroyctes. II. Kinetic analysis and substrate-binding studies. J. Biol. Chem. 1968, 243, 1771–1776.Google Scholar

Lewis, A.; Lowy, B. Human erythrocyte purine nucleoside phosphorylase: molecular weight and physical properties: a Theorell-Chance catalytic mechanism. J. Biol. Chem. 1979, 254, 9927–9932.Google Scholar

Lewis, A.; Glantz, M.Bovine brain purine-nucleoside phosphorylase purification, characterization, and catalytic mechanism. Biochemistry 1976, 15, 4451–4457.Google Scholar

Porter, D.Purine nucleoside phosphorylase: kinetic mechanism of the enzyme from calf spleen. J. Biol. Chem. 1992, 267, 7342–7351.Google Scholar

Carlson, J.; Fischer, A.Thyroid purine nucleoside phosphorylase. II. Kinetic model by alternate substrate and inhibition studies. Biochim. Biophys. Acta 1979, 566, 259–265.Google Scholar

Kline, P.; Schramm, V.Purine nucleoside phosphorylase: catalytic mechanism and transition-state analysis of the arsenolysis reaction. Biochemistry 1993, 32, 13212–13219.Google Scholar

Erion, M. D.; Stoeckler, J. D.; Guida, W. C.; Walter, R. L.; Ealick, S. E.Purine nucleoside phosphorylase. 2. Catalytic mechanism. Biochemistry 1997, 36, 11735–11748.Google Scholar

Ghanem, M.; Saen-Oon, S.; Zhadin, N.; Wing, C.; Cahill, S.; Schwartz, S.; Callender, R.; Schramm, V.Tryptophan-free human PNP reveals catalytic site interactions. Biochemistry 2008, 47, 3202–3215.Google Scholar

Kline, P.; Schramm, V.Purine nucleoside phosphorylase: inosine hydrolysis, tight binding of the hypoxanthine intermediate, and third-the-sites reactivity. Biochemistry 1992, 31, 5964–5973.Google Scholar

Lewandowicz, A.; Schramm, V.Transition state analysis for human and Plasmodium falciparum purine nucleoside phosphorylases. Biochemistry 2004, 43, 1458–1468.Google Scholar

Rising, K. A.; Schramm, V. L.Transition state analysis of NAD+ hydrolysis by the cholera toxin catalytic subunit. J. Am. Chem. Soc. 1997, 119, 27–37.Google Scholar

Stein, R.; Cordes, E.Kinetic alpha-deuterium isotope effects for Escherichia coli purine nucleoside phosphorylase-catalyzed phosphorolysis of adenosine and inosine. J. Biol. Chem. 1981, 256, 767–772.Google Scholar

Lehikoinen, P.; Sinnott, M.; Krenitsky, T.Investigation of alpha-deuterium kinetic isotope effects on the purine nucleoside phosphorylase reaction by the equilibrium-perturbation technique. Biochem. J. 1989, 257, 355–359.Google Scholar

Parks, R. E.; Agarwal, R. P. In: The Enzymes, Boyer, P. D.; Ed. New York, NY: Academic Press; 1972, Vol. 7, 483–514.

Schramm, V.; Shi, W.Atomic motion in enzymatic reaction coordinates. Curr. Opin. Struct. Biol. 2001, 11, 657–665.Google Scholar

Birck, M.; Schramm, V.Nucleophilic participation in the transition state for human thymidine phosphorylase. J. Am. Chem. Soc. 2004, 126, 2447–2453.Google Scholar

Kline, P.; Schramm, V.Pre-steady-state transition-state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase. Biochemistry 1995, 34, 1153–1162.Google Scholar

Horenstein, B.; Parkin, D.; Estupiñán, B.; Schramm, V.Transition-state analysis of nucleoside hydrolase from Crithidia fasciculata. Biochemistry 1991, 30, 10788–10795.Google Scholar

Scheuring, J.; Berti, P.; Schramm, V.Transition-state structure for the ADP-ribosylation of recombinant gialpha1 subunits by pertussis toxin. Biochemistry 1998, 37, 2748–2758.Google Scholar

Scheuring, J.; Schramm, V.Kinetic isotope effect characterization of the transition state for oxidized nicotinamide adenine dinucleotide hydrolysis by pertussis toxin. Biochemistry 1997, 36, 4526–4534.Google Scholar

Scheuring, J.; Schramm, V.Pertussis toxin: transition state analysis for ADP-ribosylation of G-protein peptide alphai3C20. Biochemistry 1997, 36, 8215–8223.Google Scholar

Berti, P. J.; Blanke, S. R.; Schramm, V. L.Transition state structure for the hydrolysis of NAD+ catalyzed by diphtheria toxin. J. Am. Chem. Soc. 1997, 119, 12079–12088.Google Scholar

Parkin, D. W.; Leung, H. B.; Schramm, V. L.Synthesis of nucleotides with specific radiolabels in ribose: primary 14C and secondary 3H kinetic isotope effects on acid-catalyzed glycosidic bond hydrolysis of AMP, dAMP, and inosine. J. Biol. Chem. 1984, 259, 9411–9417.Google Scholar

Parkin, D. W.; Schramm, V. L.Effects of allosteric activation on the primary and secondary kinetic isotope effects for three AMP nucleosidases. J. Biol. Chem. 1984, 259, 9418–9425.Google Scholar

Parkin, D.; Schramm, V.Catalytic and allosteric mechanism of amp nucleosidase from primary, beta-secondary, and multiple heavy atom kinetic isotope effects. Biochemistry 1987, 26, 913–920.Google Scholar

Parikh, S.; Schramm, V.Transition state structure for ADP-ribosylation of eukaryotic elongation factor 2 catalyzed by diphtheria toxin. Biochemistry 2004, 43, 1204–1212.Google Scholar

Parkin, D.; Mentch, F.; Banks, G.; Horenstein, B.; Schramm, V.Transition-state analysis of a Vmax mutant of AMP nucleosidase by the application of heavy-atom kinetic isotope effects. Biochemistry 1991, 30, 4586–4594.Google Scholar

Hunt, C.; Gillani, N.; Farone, A.; Rezaei, M.; Kline, P.Kinetic isotope effects of nucleoside hydrolase from Escherichia coli. Biochim. Biophys. Acta 2005, 1751, 140–149.Google Scholar

Singh, V.; Schramm, V.Transition-state structure of human 5′-methylthioadenosine phosphorylase. J. Am. Chem. Soc. 2006, 128, 14691–14696.Google Scholar

Singh, V.; Luo, M.; Brown, R.; Norris, G.; Schramm, V.Transition-state structure of Neisseria meningitides 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase. J. Am. Chem. Soc. 2007, 129, 13831–13833.Google Scholar

Chen, X. Y.; Berti, P. J.; Schramm, V. L.Ricin A-chain: kinetic isotope effects and transition state structure with stem-loop RNA. J. Am. Chem. Soc. 2000, 122, 1609–1617.Google Scholar

Chen, X. Y.; Berti, P. J.; Schramm, V. L.Transition-state analysis for depurination of DNA by ricin A-chain. J. Am. Chem. Soc. 2000, 122, 6527–6534.Google Scholar

Werner, R.; Stivers, J.Kinetic isotope effect studies of the reaction catalyzed by uracil DNA glycosylase: evidence for an oxocarbenium ion-uracil anion intermediate. Biochemistry 2000, 39, 14054–14064.Google Scholar

Singh, V.; Lee, J.; Núñez, S.; Howell, P.; Schramm, V.Transition state structure of 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli and its similarity to transition state analogues. Biochemistry 2005, 44, 11647–11659.Google Scholar

Singh, V.; Schramm, V.Transition-state analysis of S. pneumoniae 5′-methylthioadenosine nucleosidase. J. Am. Chem. Soc. 2007, 129, 2783–2795.Google Scholar

Munns, A.; Tollin, P.The crystal and molecular structure of inosine. Acta Crystallogr. B 1970, 26, 1101–1113.Google Scholar

Miles, R. W.; Tyler, P. C.; Furneaux, R. H.; Bagdassarian, C. K.; Schramm, V. L.One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry 1998, 37, 8615–8621.Google Scholar

Sauve, A.; Cahill, S.; Zech, S.; Basso, L.; Lewandowicz, A.; Santos, D.; Grubmeyer, C.; Evans, G.; Furneaux, R.; Tyler, P.; McDermott, A.; Girvin, M.; Schramm, V.Ionic states of substrates and transition state analogues at the catalytic sites of N-ribosyltransferases. Biochemistry 2003, 42, 5694–5705.Google Scholar

Schramm, V. L.Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents. Biochim. Biophys. Acta 2002, 1587, 107–117.Google Scholar

Bzowska, A.; Kulikowska, E.; Darzynkiewicz, E.; Shugar, D.Purine nucleoside phosphorylase. structure-activity relationships for substrate and inhibitor properties of N-1-, N-7-, and C-8-substituted analogues; differentiation of mammalian and bacterial enzymes with N-1-methylinosine and guanosine. J. Biol. Chem. 1988, 263, 9212–9217.Google Scholar

Bagdassarian, C. K.; Schramm, V. L.; Schwartz, S. D.Molecular electrostatic potential analysis for enzymatic substrates, competitive inhibitors, and transition-state inhibitors. J. Am. Chem. Soc. 1996, 118, 8825–8836.Google Scholar

Braunheim, B.; Miles, R.; Schramm, V.; Schwartz, S.Prediction of inhibitor binding free energies by quantum neural networks: nucleoside analogues binding to trypanosomal nucleoside hydrolase. Biochemistry 1999, 38, 16076–16083.Google Scholar

Evans, G. B.; Furneaux, R. H.; Gainsford, G. J.; Schramm, V. L.; Tyler, P. C.Synthesis of transition state analogue inhibitors for purine nucleoside phosphorylase and N-riboside hydrolases. Tetrahedron 2000, 56, 3053–3062.Google Scholar

Evans, G.; Furneaux, R.; Hutchison, T.; Kezar, H.; Morris, P. J.; Schramm, V.; Tyler, P.Addition of lithiated 9-deazapurine derivatives to a carbohydrate cyclic imine: convergent synthesis of the aza-C-nucleoside Immucillins. J. Org. Chem. 2001, 66, 5723–5730.Google Scholar

Ealick, S.; Rule, S.; Carter, D.; Greenhough, T.; Babu, Y.; Cook, W.; Habash, J.; Helliwell, J.; Stoeckler, J.; Parks, R. J.Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 Å resolution. J. Biol. Chem. 1990, 265, 1812–1820.Google Scholar

Mao, C.; Cook, W. J.; Zhou, M.; Federov, A. A.; Almo, S. C.; Ealick, S. E.Calf spleen purine nucleoside phosphorylase complexed with substrates and substrate analogues. Biochemistry 1998, 37, 7135–7146.Google Scholar

Wang, F.; Miles, R. W.; Kicska, G.; Nieves, E.; Schramm, V. L.; Angeletti, R. H.Immucillin-H binding to purine nucleoside phosphorylase reduces dynamic solvent exchange. Protein Sci. 2000, 9, 1660–1668.Google Scholar

Fedorov, A.; Shi, W.; Kicska, G.; Fedorov, E.; Tyler, P.; Furneaux, R.; Hanson, J.; Gainsford, G.; Larese, J.; Schramm, V.; Almo, S.Transition state structure of purine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis. Biochemistry 2001, 40, 853–860.Google Scholar

Shi, W.; Li, C.; Tyler, P.; Furneaux, R.; Cahill, S.; Girvin, M.; Grubmeyer, C.; Schramm, V.; Almo, S.The 2.0 Å structure of malarial purine phosphoribosyltransferase in complex with a transition-state analogue inhibitor. Biochemistry 1999, 38, 9872–9880.Google Scholar

Shi, W.; Li, C.; Tyler, P.; Furneaux, R.; Grubmeyer, C.; Schramm, V.; Almo, S.The 2.0 Å structure of human hypoxanthine-guanine phosphoribosyltransferase in complex with a transition-state analog inhibitor. Nat. Struct. Biol. 1999, 6, 588–593.Google Scholar

Héroux, A.; White, E.; Ross, L.; Davis, R.; Borhani, D.Crystal structure of Toxoplasma gondii hypoxanthine-guanine phosphoribosyltransferase with XMP, pyrophosphate, and two Mg(2+) ions bound: insights into the catalytic mechanism. Biochemistry 1999, 38, 14495–14506.Google Scholar

Tao, W.; Grubmeyer, C.; Blanchard, J.Transition state structure of Salmonella typhimurium orotate phosphoribosyltransferase. Biochemistry 1996, 35, 14–21.Google Scholar

Sauve, A.; Wolberger, C.; Schramm, V.; Boeke, J.The biochemistry of sirtuins. Annu. Rev. Biochem. 2006, 75, 435–465.Google Scholar

Bianchet, M.; Seiple, L.; Jiang, Y.; Ichikawa, Y.; Amzel, L.; Stivers, J.Electrostatic guidance of glycosyl cation migration along the reaction coordinate of uracil DNA glycosylase. Biochemistry 2003, 42, 12455–12460.Google Scholar

Vocadlo, D.; Davies, G.; Laine, R.; Withers, S.Catalysis by hen egg-white lysozyme proceeds via a covalent intermediate. Nature 2001, 412, 835–838.Google Scholar

Kicska, G. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Shi, W. X.; Fedorov, A.; Lewandowicz, A.; Cahill, S. M.; Almo, S. C.; Schramm, V. L.Atomic dissection of the hydrogen bond network for transition-state analogue binding to purine nucleoside phosphorylase. Biochemistry 2002, 41, 14489–14498.Google Scholar

Evans, G.; Furneaux, R.; Lewandowicz, A.; Schramm, V.; Tyler, P.Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase. J. Med. Chem. 2003, 46, 3412–3423.Google Scholar

Lewandowicz, A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Schramm, V. L. Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J. Biol. Chem. 2003, 278, 31465–31468.Google Scholar

Jiang, Y.; Ichikawa, Y.; Stivers, J.Inhibition of uracil DNA glycosylase by an oxacarbenium ion mimic. Biochemistry 2002, 41, 7116–7124.Google Scholar

Berti, P.; McCann, J.Toward a detailed understanding of base excision repair enzymes: transition state and mechanistic analyses of N-glycoside hydrolysis and N-glycoside transfer. Chem. Rev. 2006, 106, 506–555.Google Scholar

Evans, G.; Furneaux, R.; Lewandowicz, A.; Schramm, V.; Tyler, P.Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. J. Med. Chem. 2003, 46, 5271–5276.Google Scholar

Evans, G.; Furneaux, R.; Tyler, P.; Schramm, V.Synthesis of a transition state analogue inhibitor of purine nucleoside phosphorylase via the mannich reaction. Org. Lett. 2003, 5, 3639–3640.Google Scholar

Furneaux, R.; Tyler, P.Improved syntheses of 3H,5H-pyrrolo[3,2-d]pyrimidines. J. Org. Chem. 1999, 64, 8411–8412.Google Scholar

Lewandowicz, A.; Shi, W. X.; Evans, G. B.; Tyler, P. C.; Furneaux, R. H.; Basso, L. A.; Santos, D. S.; Almo, S. C.; Schramm, V. L.Over-the-barrier transition state analogues and crystal structure with mycobacterium tuberculosis purine nucleoside phosphorylase. Biochemistry 2003, 42, 6057–6066.Google Scholar

Taylor Ringia, E. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Murkin, A. S.; Schramm, V. L.Transition state analogue discrimination by related purine nucleoside phosphorylases. J. Am. Chem. Soc. 2006, 128, 7126–7127.Google Scholar

Clinch, K.; Evans, G.; Fleet, G.; Furneaux, R.; Johnson, S.; Lenz, D.; Mee, S.; Rands, P.; Schramm, V.; Taylor Ringia, E.; Tyler, P.Syntheses and bio-activities of the L-enantiomers of two potent transition state analogue inhibitors of purine nucleoside phosphorylases. Org. Biomol. Chem. 2006, 4, 1131–1139.Google Scholar

Rinaldo-Matthis, A.; Murkin, A.; Ramagopal, U.; Clinch, K.; Mee, S.; Evans, G.; Tyler, P.; Furneaux, R.; Almo, S.; Schramm, V. L-enantiomers of transition state analogue inhibitors bound to human purine nucleoside phosphorylase. J. Am. Chem. Soc. 2008, 130, 842–844.Google Scholar

Lewandowicz, A.; Ringia, E.; Ting, L.; Kim, K.; Tyler, P.; Evans, G.; Zubkova, O.; Mee, S.; Painter, G.; Lenz, D.; Furneaux, R.; Schramm, V.Energetic mapping of transition state analogue interactions with human and Plasmodium falciparum purine nucleoside phosphorylases. J. Biol. Chem. 2005, 280, 30320–30328.Google Scholar

Nunez, S.; Wing, C.; Antoniou, D.; Schramm, V. L.; Schwartz, S. D.Insight into catalytically relevant correlated motions in human purine nucleoside phosphorylase. J. Phys. Chem. A 2006, 110, 463–472.Google Scholar

Murkin, A.; Tyler, P.; Schramm, V.Transition-state interactions revealed in purine nucleoside phosphorylase by binding isotope effects. J. Am. Chem. Soc. 2008, 130, 2166–2167.Google Scholar

Kicska, G.; Long, L.; Hörig, H.; Fairchild, C.; Tyler, P.; Furneaux, R.; Schramm, V.; Kaufman, H.Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4593–4598.Google Scholar

Bantia, S.; Miller, P. J.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Kilpatrick, J. M.; Morris, P. E.; Hutchison, T. L.; Montgomery, J. A.; Sandhu, J. S.Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) – a novel potent and orally active immunosuppressive agent. Int. Immunopharmacol. 2001, 1, 1199–1210.Google Scholar

Galmarini, C.Drug evaluation: forodesine – PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor. IDrugs 2006, 9, 712–722.Google Scholar

Larson, R. A.Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. Semin. Oncol. 2007, 34, S13–20.Google Scholar

Korycka, A.; Blonski, J. Z.; Robak, T.Forodesine (BCX-1777, Immucillin H) – a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev. Med. Chem. 2007, 7, 976–983.Google Scholar

Gore, L.; Stelljes, M.; Quinones, R.Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?Semin. Oncol. 2007, 34, S35–39.Google Scholar

Gandhi, V.; Balakrishnan, K.Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. Semin. Oncology 2007, 34, S8–S12.Google Scholar

Furman, R. R.; Hoelzer, D.Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies. Semin. Oncol. 2007, 34, S29–S34.Google Scholar

Duvic, M.; Foss, F. M.Mycosis fungoides: pathophysiology and emerging therapies. Semin. Oncol. 2007, 34, S21–28.Google Scholar

Duvic, M.Systemic monotherapy vs combination therapy for ctcl: rationale and future strategies. Oncology 2007, 21, 33–40.Google Scholar

,BioCryst Pharmaceuticals Inc., Forodesine, October 7, 2009, http://www.biocryst.com/forodesine.

Semeraro, T.; Lossani, A.; Botta, M.; Ghiron, C.; Alvarez, R.; Manetti, F.; Mugnaini, C.; Valensin, S.; Focher, F.; Corelli, F.Simplified analogues of Immucillin-G retain potent human purine nucleoside phosphorylase inhibitory activity. J. Med. Chem. 2006, 49, 6037–6045.Google Scholar

Taylor, E.; Clinch, K.; Kelly, P.; Li, L.; Evans, G.; Tyler, P.; Schramm, V.Acyclic ribooxacarbenium ion mimics as transition state analogues of human and malarial purine nucleoside phosphorylases. J. Am. Chem. Soc. 2007, 129, 6984–6985.Google Scholar

Acronym for 2′-Deoxy-2′-Amino-Tetritol-N-(9-Methylene)-ImmH but the IUPAC name is 9-deaza-9-[[(2R,3S)-1,3,4-trihydroxybutan-2-ylamino]methyl]hypoxanthine. This acronym first appeared in Taylor et al., but as an oversight, was never defined; DATMe-ImmH is compound 19 in that manuscript.

Taylor, E. A.; Rinaldo-Matthis, A.; Li, L.; Ghanem, M.; Hazleton, K. Z.; Cassera, M. B.; Almo, S. C.; Schramm, V. L.Anopheles gambiae purine nucleoside phosphorylase: catalysis, structure, and inhibition. Biochemistry 2007, 46, 12405–12415.Google Scholar

Agarwal, R.; Spector, T.; Parks, R. J.Tight-binding inhibitors. IV. Inhibition of adenosine deaminases by various inhibitors. Biochem. Pharmacol. 1977, 26, 359–367.Google Scholar

Tokutake, N.; Hiratake, J.; Katoh, M.; Irie, T.; Kato, H.; Oda, J.Design, synthesis and evaluation of transition-state analogue inhibitors of Escherichia coli gamma-glutamylcysteine synthetase. Bioorg. Med. Chem. 1998, 6, 1935–1953.Google Scholar

von Itzstein, M.; Wu, W.; Kok, G.; Pegg, M.; Dyason, J.; Jin, B.; Phan, T.; Smythe, M.; White, H.; Oliver, S.Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418–423.Google Scholar

Bolin, J.; Filman, D.; Matthews, D.; Hamlin, R.; Kraut, J.Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 Å resolution. I. General features and binding of methotrexate. J. Biol. Chem. 1982, 257, 13650–13662.Google Scholar

Kimble, E.; Hadala, J.; Ludewig, R.; Peters, P.; Greenberg, G.; Xiao, G.; Guida, W.; McQuire, L.; Simon, P.The biochemical and pharmacological activity of 9-benzyl-9-deazaguanine, a potent purine nucleoside phosphorylase (PNP) inhibitor. Inflamm. Res. 1995, 44(suppl. 2), S181–S182.Google Scholar

Perzborn, E.; Strassburger, J.; Wilmen, A.; Pohlmann, J.; Roehrig, S.; Schlemmer, K. H.; Straub, A.In vitro and in vivo studies of the novel antithrombotic agent bay 59–7939 – an oral, direct factor Xa inhibitor. J. Thromb. Haemost. 2005, 3, 514–521.Google Scholar

Taylor Ringia, E. A.; Schramm, V. L.Transition states and inhibitors of the purine nucleoside phosphorylase family. Curr. Top. Med. Chem. 2005, 5, 1237–1258.Google Scholar

Kicska, G. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Kim, K.; Schramm, V. L.Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum. J. Biol. Chem. 2002, 277, 3219–3225.Google Scholar

Barsacchi, D.; Cappiello, M.; Tozzi, M.; Del Corso, A.; Peccatori, M.; Camici, M.; Ipata, P.; Mura, U.Purine nucleoside phosphorylase from bovine lens: purification and properties. Biochim. Biophys. Acta 1992, 1160, 163–170.Google Scholar

Stoeckler, J. D.; Poirot, A. F.; Smith, R. M.; Parks, R. E.; Ealick, S. E.; Takabayashi, K.; Erion, M. D.Purine nucleoside phosphorylase. 3. Reversal of purine base specificity by site-directed mutagenesis. Biochemistry 1997, 36, 11749–11756.Google Scholar

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the PDF of this chapter is currently unknown and may be updated in the future.